AN2 Therapeutics Debt to Equity

The latest debt-to-equity ratio for ANTX is 0.0. That is below the sector sector average of 0.2. Investors often review this figure alongside AN2 Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, ANTX currently prints 0.0 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at AN2 Therapeutics's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.0 for AN2 Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with ANTX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting ANTX's debt-to-equity ratio (0.0), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.